Edesa Biotech, Inc. (EDSA)
Develops experimental drug treatments for inflammatory and immune diseases
$5.11-0.05%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+138.6%
The outlook
EDSA trades near its 52-week low, with the price sitting about a quarter of the way up from its yearly bottom. Analyst sentiment is mixed overall, though the average price target implies significant upside from current levels. The stock shows neutral momentum against its moving averages.
What’s behind the score
Price trendMixed vs its moving averages
52-week range22% of the way from its 52-week low to high
Price targetAvg target +220% vs current price
Analyst price target
~12-month · 3 analysts$16.33average target+219.9% vs now
Now $5.11
Low $9.00High $21.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
$20.32
52-wk low
$0.72
50-day avg
$7.45
200-day avg
$4.86
Trailing P/E
—